aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Arbor Biotechnologies, founded as a life sciences company, is dedicated to pushing the boundaries of biodiscovery. Their core mission is to revolutionize the treatment of genetic diseases by developing next-generation gene editing tools. Utilizing a diverse set of technologies, including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor focuses on creating innovative solutions to address the root causes of genetic disorders.
Notable affiliated individuals include co-founders Feng Zhang and David Walt, both prominent figures in biotechnology. Arbor has garnered significant investment from leading venture capital firms, bolstering its research and development capabilities. Key achievements include the development of a diverse toolbox of novel gene editors, positioning Arbor at the forefront of genetic disease treatment. The company's impact lies in its potential to deliver functional cures for previously untreatable genetic conditions, marking a significant advancement in personalized medicine.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Gene Editing
Technology
AI, Genomics
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Arbor Biotechnologies founded?
Arbor Biotechnologies was founded in 2016.
Where is Arbor Biotechnologies’s headquarters located?
Arbor Biotechnologies’s headquarters is located in Cambridge, MA, US.
When was Arbor Biotechnologies’s last funding round?
Arbor Biotechnologies’s most recent funding round was for $215M (USD) in November 2021.
How many employees does Arbor Biotechnologies have?
Arbor Biotechnologies has 170 employees as of Feb 5, 2024.
How much has Arbor Biotechnologies raised to-date?
As of July 05, 2023, Arbor Biotechnologies has raised a total of $230.6M (USD) since Nov 9, 2021.
Add Comparison
Total Raised to Date
$230.6M
USD
Last Update Nov 9, 2021
Last Deal Details
$215M
USD
Nov 9, 2021
Series B
Total Employees Over Time
170
As of Feb 2024
Arbor Biotechnologies Address
790 Memorial Drive.
Cambridge,
Massachusetts
02139
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts